Corvus Pharmaceuticals CRVS Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.
The official record: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corvus Pharmaceuticals's change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corvus Pharmaceuticals's change in accrued liabilities?
- Corvus Pharmaceuticals (CRVS) reported change in accrued liabilities of $499K in Q1 2026.
- How has Corvus Pharmaceuticals's change in accrued liabilities changed year-over-year?
- Corvus Pharmaceuticals's change in accrued liabilities increased by 241.8% year-over-year, from $146K to $499K.
- What is the long-term trend for Corvus Pharmaceuticals's change in accrued liabilities?
- Over 3 years (2021 to 2025), Corvus Pharmaceuticals's change in accrued liabilities has grown at a 74.1% compound annual growth rate (CAGR), from -$523K to $2.76M.
- What does change in accrued liabilities mean?
- Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.